Ansys: The Hidden Engine Behind the Next Healthcare Revolution
What is Ansys? Ansys delivers high-fidelity multiphysics simulation and digital-twin capabilities used to model devices, implants, fluid–structure interactions, and manufacturing processes across life sciences. The platform combines finite-element (FE), computational fluid dynamics (CFD), system-level modeling, and data-driven surrogates to predict device behaviour, patient–device interactions, and process outcomes under varied scenarios. Use cases include implantable device […]
Feature Categories
What is Ansys?
Ansys delivers high-fidelity multiphysics simulation and digital-twin capabilities used to model devices, implants, fluid–structure interactions, and manufacturing processes across life sciences. The platform combines finite-element (FE), computational fluid dynamics (CFD), system-level modeling, and data-driven surrogates to predict device behaviour, patient–device interactions, and process outcomes under varied scenarios.
Use cases include implantable device design, hemodynamic and airflow simulations, sterilisation and packaging validation, virtual patient cohorts for feasibility studies, and production line optimisation. The tool emphasises validated solvers, scalable HPC execution, and traceable model provenance to support engineering decisions and regulated workflows.
Why Leading Healthcare Teams Trust Ansys
- Ansys collaborates with regulatory bodies including TÜV SÜD (a global testing organisation with over 28,000 employees across 1,000 locations in 50 countries) to help manufacturers meet global regulatory compliance standards through high-fidelity simulation and automated digital processes.
- Ansys holds SOC 2 Type II certification, ISO 27001, and ISO 27017 certifications, with cybersecurity management following ISO and NIST frameworks for internal assessments and third-party evaluations.
- Ansys SCADE Suite KCG and SCADE Display KCG are certified by TÜV SÜD to support ISO 26262 compliance up to ASIL D, the highest safety requirement for automotive applications.
- Ansys processes personal data for license compliance verification including geographic location, usernames, email addresses, IP addresses, and ensures data transfers comply with GDPR and PIPL (China's Personal Information Protection Law) through Standard Contractual Clauses and approved data transfer mechanisms.
- Data protection measures include encryption at rest using cryptography, data classification standards for lifecycle tracking, and data retention policies that ensure data is deleted and destroyed upon expiration.
- Ansys virtual homologation toolchain launched with Microsoft, Kontrol, and TÜV SÜD provides integrated workflows enabling certified automotive safety testing (crash safety, active safety, and functional safety) and reduces reliance on costly physical prototypes.
- Ansys maintains an open digital twin solution ecosystem meaning users are not required to use only Ansys tools, with founding partnerships in the Digital Twin Consortium alongside Dell, GE Digital, Northrop Grumman, and Microsoft.
- Ansys acquired Lumerical (2020) for silicon photonic simulation, Analytical Graphics Inc. (2020) for $700 million for mission-driven aerospace and defense applications, and Zemax (2021) for optical imaging system simulation, with completed acquisition of Zemax for approximately $410 million.
- Synopsys completed its $35 billion acquisition of Ansys in July 2025, combining EDA and multiphysics simulation capabilities to create an integrated AI-powered product development platform spanning chip design to full-system validation.
- Ansys digital twins enable real-time monitoring of physical assets, predictive maintenance, and performance optimisation while reducing unplanned downtime costs and equipment failure risks across aerospace, automotive, manufacturing, energy, and healthcare sectors.
Top 3 Pain Points Ansys Fixes in Healthcare
| Problem | How Ansys Solves It |
|---|---|
| 1. High Cost and Time of Physical Prototyping | Ansys enables virtual testing and simulation of medical devices and systems, reducing the need for multiple physical prototypes and cutting R&D costs by up to 50%. |
| 2. Limited Insight into Real-World Device Performance | By creating digital twins of devices and patient environments, Ansys allows engineers to test performance, durability, and safety under diverse physiological and environmental conditions—before human trials. |
| 3. Slow Regulatory and Design Iteration Cycles | With validated, high-fidelity multiphysics simulations and automated workflows, Ansys accelerates design optimization and documentation, helping teams meet compliance requirements more efficiently. |
Feature Category Summary: Ansys
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Ansys positions its simulation and digital twin tools as enabling verification, validation, and uncertainty quantification following FDA standards for patient-specific models, and collaborates with partners like Simq specifically to address regulatory requirements for digital twins in medicine, but there is no claim that Ansys Twin Builder or TwinAI themselves are FDA/EMA-cleared medical devices or formally GxP-validated platforms. | NA |
| Clinical Trial Support | Ansys materials describe using digital twins and causal AI for in silico clinical trials, including a partnership with Nova In Silico to integrate Ansys Granta with the Jinko trial simulation platform, and Ansys blogs note that digital twins can track patients in real time to predict trajectories and reduce the scope and cost of trials. | YES |
| Supply Chain & Quality | Ansys highlights pharma and biopharma manufacturing use cases where digital twins monitor drug production processes in real time, identify optimal process conditions, and check critical quality attributes at scale to ensure effective and robust manufacturing of biological medicines, but there is no explicit mention of counterfeit detection or serialization features. | YES |
| Efficiency & Cost-Saving | Content on biopharma digital twins states that simulations and digital twins reduce the need for physical experiments, accelerate drug development, optimize processes, and cut R&D costs, including examples of substantial efficiency gains in drug delivery and manufacturing, and a broader Ansys digital twin guide emphasizes cost reduction via virtual testing and predictive maintenance. | YES |
| Scalable / Enterprise-Grade | Ansys Twin Builder and TwinAI are promoted as platforms to create, validate, deploy, and scale hybrid digital twins across industries with stringent performance and safety requirements, and third-party overviews describe their use in pharma and biopharma manufacturing for lifecycle management and optimization, implying enterprise-grade scalability, although specific large pharma deployments are referenced generally rather than by named case studies. | YES |
| HIPAA Compliant | Neither Ansys healthcare nor digital twin documentation explicitly claims HIPAA compliance, HIPAA-qualified hosting, or availability of BAAs for deployments involving protected health information. | NA |
| Clinically Validated | Ansys showcases collaborations (for example with Simq and Oklahoma State) where digital twins and simulations improve drug delivery efficiency and support patient-specific modeling, but public sources describe engineering and pharmacological validation rather than formal clinical outcome trials that establish a particular Ansys digital twin configuration as a cleared clinical diagnostic or therapeutic tool. | NA |
| EHR Integration | Healthcare-related descriptions of Ansys digital twins mention integrating multi-omics data, sensor data, and other clinical information to track patients and processes, but there is no explicit documentation of native integration with specific EHR systems or standards such as HL7 or FHIR for direct point-of-care connectivity. | NA |
| Explainable AI | The hybrid analytics tools in Ansys Twin Builder are described as combining physics-based models with ML so that the physics behavior is preserved and parameter learning remains explainable within the model context, giving engineers insight into root causes of system behavior, although the fusion ML portion is noted as not inherently explaining missing physics. | YES |
| Real-Time Analytics | Ansys states that digital twins built with Twin Builder and TwinAI support real-time systems analysis, real-time monitoring of biopharma production, and prediction of performance to schedule predictive maintenance and process interventions, with continuous data synchronization between physical assets and virtual twins. | YES |
| Bias Detection | Available Ansys documents on digital twins and hybrid analytics discuss accuracy, uncertainty, and physics/ML fusion but do not describe built-in features for detecting or quantifying algorithmic bias across demographic or clinical sub-cohorts in healthcare applications. | NA |
| Ethical Safeguards | Industry and review articles acknowledge regulatory, data protection, and ethical challenges for digital twins in healthcare, but Ansys product materials do not specify configurable consent management, human-in-the-loop override controls for clinical decisions, or embedded AI governance/use-case restriction modules within Twin Builder or TwinAI. | NA |
Risks & Limitations: Ansys
-
Predictive accuracy depends on input model fidelity, material data and boundary conditions; poor or incomplete inputs reduce reliability.
-
Outputs are decision-support; domain experts must validate results before clinical, regulatory or manufacturing actions.
-
High-fidelity simulations can be compute-intensive and require HPC/cloud budgeting and operational support.
-
Integration with PLM, MES, clinical imaging or process historians may require significant IT effort and data mapping.
-
Surrogate models and reduced-order twins require careful validation; over-reliance without re-validation risks incorrect operational decisions.
-
Regulatory acceptance varies by use case—formal verification/validation and documented provenance are required for regulated submissions.
-
Model drift: design changes, material updates or new clinical evidence can degrade surrogate accuracy—ongoing monitoring and revalidation are required.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
